siRNA and miRNA Gene Silencing

Methods for Selecting Effective siRNA Sequences by using Statistical and Clustering Techniques.- Deciphering the Code of Innate Immunity Recognition of siRNAs.- Targeted Delivery of Antisense Oligonucleotides and siRNAs into Mammalian Cells.- Local and Systemic Delivery of siRNAs for Oligonucleotides Therapy.- Imaging of siRNA Delivery and Silencing.- Recent Advances in Magnetofection and Its Potential to Deliver siRNAs In Vitro.- In Vitro and In Vivo Gene Silencing by TransKingdom RNAi (tkRNAi).- Bacterial Delivery of siRNAs: A New Approach to Solid Tumor Therapy.- The Therapeutic Potential of LNA-modified siRNAs: Reduction of Off-target Effects by Chemical Modification of the siRNA Sequence.- pSM155 and pSM30 Vectors for miRNA and shRNA Expression.- Targeting Oncogenes with siRNAs.- Targeting Stromal-cancer Cell Interactions with siRNAs.- Therapeutic Potential of siRNA-mediated Targeting of Urokinase Plasminogen Activator, Its Receptor, and Matrix Metalloproteinases.- Silencing of HIF-1#x03B1; by RNA Interference in Human Glioma Cells In Vitro and In Vivo.- RNA Interference-Mediated Validation of Genes Involved in Telomere Maintenance and Evasion of Apoptosis as Cancer Therapeutic Targets.- Treating Respiratory Viral Diseases with Chemically Modified, Second Generation Intranasal siRNAs.- Progress in the Therapeutic Applications of siRNAs Against HIV-1.- Protein Components of the microRNA Pathway and Human Diseases.- Intron-Mediated RNA Interference and microRNA Biogenesis.- Emergence of a Complex Relationship between HIV-1 and the microRNA Pathway.- Synthetic microRNA Targeting Glioma-associated Antigen-1 Protein.- Therapeutic Targeting of Gene Expression by siRNAs Directed Against BCR-ABL Transcripts in a Patient with Imatinib-Resistant Chronic Myeloid Leukemia.